Global – December 31, 2025 — Novartis International AG significantly expanded its investment in artificial intelligence (AI) across the biopharma value chain in 2025, allocating approximately $480 million toward AI platforms, strategic collaborations, and enterprise‑wide digital transformation. These investments, bolstered by key partnerships and deal-making activity, reinforce Novartis’ strategic focus on using AI to accelerate innovation, optimize clinical programs, and strengthen commercialization across multiple therapeutic areas.
AI Investments and Strategic Initiatives in 2025
Novartis deployed AI across discovery, development, and commercialization with a combination of internal capability building and external dealmaking:
• AI‑Enabled Discovery and Target Identification
Novartis enhanced early‑stage research with AI platforms that integrate genomic, proteomic, and phenotypic data to prioritize novel targets and optimize lead molecules with improved selection confidence.
• Predictive R&D and Clinical Development
AI tools were deployed to support adaptive trial design, predictive patient stratification, and digital biomarkers — improving predictive modeling for safety, efficacy, and disease progression across key oncology and immunology programs.
• Commercial and Market Access Analytics
Advanced analytics guided payer segmentation, real‑world evidence (RWE) modeling, and launch forecasting, enabling more effective pricing and market access planning for new therapies nearing commercialization.
• Internal AI Infrastructure and Talent Expansion
Novartis upgraded cloud computing capacity, scalable AI data platforms, and in‑house AI talent to support machine learning workflows across functions.
In total, the company’s AI investment in 2025 reached approximately $480 million, reflecting a strategic push toward enterprise‑wide AI adoption.
Key AI Deals That Defined Novartis’ 2025 Strategy
Novartis complemented internal investment with strategic external deals to accelerate its AI capabilities:
1. Multi‑Year Collaboration with a Leading AI Drug Discovery Platform
Novartis entered into a multi‑million‑dollar collaboration with an advanced AI drug discovery specialist to co‑develop predictive models for complex targets and identify candidates in areas such as neurological and immuno‑oncology.
2. AI Platform Licensing for Brain Penetrant Therapeutics
The company secured a deal to license an AI‑driven platform focused on modeling blood–brain barrier penetration, enhancing its ability to design therapies for central nervous system (CNS) disorders.
3. Partnership to Integrate Large‑Scale Clinical and Real‑World Data
Novartis expanded a collaboration with a consortium of clinical AI analytics firms to integrate real‑world datasets, improving outcome prediction, trial enrichment strategies, and post‑market safety surveillance.
4. Joint Development Agreement for Next‑Generation Biomarker Discovery
In 2025, Novartis signed a joint development agreement with a machine learning innovator to co‑develop digital biomarker platforms, targeting earlier disease detection and prognostic precision in oncology and rare diseases.
These deals reflect Novartis’ belief that combined internal and external AI capabilities accelerate both scientific insight and clinical execution.
Looking Ahead: 2026 and Beyond
Novartis expects its 2025 AI initiatives to yield strategic advantages in 2026:
- Accelerated Target to Clinic Translation: AI‑enhanced discovery models are expected to compress timelines for candidate selection and preclinical validation.
- Improved Trial Success Probability: Predictive analytics and AI‑assisted modeling support smarter trial design and patient cohort selection.
- Stronger Commercial Readiness: AI‑derived real‑world evidence and demand forecasting will strengthen payer engagement and differentiated launch strategies.
As competition escalates across therapeutic innovation, Novartis believes AI will become a core differentiator in scientific insight, clinical efficiency, and commercial impact.
Conclusion
Novartis’ $480 million AI investment in 2025, amplified by targeted strategic deals, underscores its enterprise‑wide commitment to artificial intelligence across discovery, development, and commercialization. By integrating AI internally and through high‑impact collaborations, Novartis is positioning itself to accelerate innovation and deliver meaningful therapeutic advances as it enters 2026 and beyond.
By